Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2018

View Archived Issues

Bayer patents Wnt signaling and/or tankyrase-1/2 inhibitors

Accent Therapeutics launches to create innovative therapeutics in area of epitranscriptomics

Docetaxel nanoemulsion with theranostic properties selectively targets ovarian cancer cells

Wuhan Bowo Biological Technology divulges pneumococcal protein vaccines

FDA approves thrombopoietin receptor agonist Doptelet

European Commission approves Juluca for HIV-1

FDA awards breakthrough therapy and fast track designations to Harmony's pitolisant

Prolia approved in U.S. for glucocorticoid-induced osteoporosis

Lundbeck begins clinical development with PDE1 inhibitor Lu-AF-76432

New anticancer adaptive cell therapy approach as cancer immunotherapeutic shows promise

FDA approves Lokelma for hyperkalemia

KRAS-G12C inhibitors reveal new approach to undruggable targets

FDA accepts NDA for Rifamycin SV MMX

Merck & Co.'s rVSV-ZEBOV Ebola vaccine deployed in Democratic Republic of Congo

Immunomedics submits BLA for sacituzumab govitecan for metastatic TNBC

Genentech presents first phase I data for BITS-7201A

AstraZeneca files for Japanese approval of Forxiga for type 1 diabetes

MHRA clears 4D pharma to begin phase Ib study of MRx-0518

First-in-human study shows promise of SYNT-001 in pemphigus

Glenmark submits NDA for Ryaltris for seasonal allergic rhinitis

Allergy Therapeutics reports promising topline results from phase II trial of Grass MATA MPL

New company Curevo to support GC Pharma's vaccine development work

Gilead Sciences seeks Japanese approval of sofosbuvir/velpatasvir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...